胃康宁治疗脾虚寒热瘀毒型慢性萎缩性胃炎伴胃癌前病变临床疗效及调节COX-2蛋白的机制研究  

Research on the clinical efficacy of Weikangning in the treatment of chronic atrophic gastritis with precancerous lesions of spleen deficiency and cool-heat stagnation pattern and regulation mechanism on COX-2 protein

作　　者：刘涛[1] 张霞[2] 魏玮[1] LIU Tao ZHANG Xia WEI Wei(Department of Spleen and Stomach Diseases, Wangjing Hospital, China Academy of Chinese Medicine Sciences, Beijing, 100102 Department of Traditional Chinese Medicine, Medical College of Datong University, Shanxi , 037000)

机构地区：[1]中国中医科学院望京医院脾胃病科,北京100102 [2]大同大学医学院中医系,山西大同037000

出　　处：《上海中医药杂志》2016年第11期46-48,68,共4页Shanghai Journal of Traditional Chinese Medicine

基　　金：北京市科委G20工程支撑保障项目(Z161100001816016)

摘　　要：目的观察胃康宁治疗脾虚寒热瘀毒型慢性萎缩性胃炎伴胃癌前病变患者的临床疗效及调节COX-2蛋白的机制。方法将90例脾虚寒热瘀毒型慢性萎缩性胃炎伴胃癌前病变患者随机分为治疗组和对照组,每组45例。治疗组口服胃康宁组方,对照组口服胃复春片,疗程均为12周。观察临床疗效、病理改变,比较两组中医证候积分和胃黏膜COX-2蛋白变化情况。结果 1治疗组、对照组临床总有效率分别为93.3%和57.6%;组间临床疗效比较,差异有统计学意义(P<0.05)。2治疗前后组内比较,两组炎症、萎缩、肠化生积分和总积分差异均有统计学意义(P<0.05)。组间治疗后比较,两组炎症、萎缩、肠化生积分和总积分差异均有统计学意义(P<0.05)。3治疗前后组内比较,胃痛、痞满、嘈杂、乏力、纳呆积分和总积分差异均有统计学意义(P<0.05)。组间治疗后比较,胃痛、痞满、纳呆积分和总积分差异均有统计学意义(P<0.05)。4治疗前后组内比较,治疗组COX-2值差异有统计学意义(P<0.05);组间治疗后比较,COX-2值差异有统计学意义(P<0.05)。结论胃康宁治疗脾虚寒热瘀毒型慢性萎缩性胃炎伴胃癌前病变临床疗效满意,可显著改善患者临床症状,缓解胃黏膜炎症,逆转胃黏膜萎缩和肠上皮化生,降低胃黏膜COX-2蛋白表达可能为机制之一。Objective To observe the clinical efficacy of Weikangning prescription in the treatment of chronic atrophic gastritis（CAG） of spleen deficiency and cold-heat stagnation pattern accompanied with precancerous lesion of gastric carcinoma（PLGC） and regulation mechanism on COX-2 protein.Methods Ninety cases with CAG of spleen deficiency and cold-heat stagnation pattern accompanied with PLGC were randomly divided into the treatment group and control group,45 cases in each group.The treatment group was orally treated with Weikangning prescription and the control group was orally treated with Weifuchun tablets,with a course of 12 weeks.The clinical efficacy and pathological changes were observed and the changes of TCM syndrome scores and COX-2 protein in gastric mucosa were compared between the two groups.Results 1 The total effective rate in the treatment group and control group was 93.3% and 57.6% respectively; there was statistically significant difference on the clinical efficacy between the two groups（P〈0.05）.2Comparison of treatment before and after,there were statistically significant differences on the inflammation,atrophy,intestinal metaplasia and total score in both groups（P〈0.05）.Comparison between the two groups,there were statistically significant differenceson the inflammation,atrophy,intestinal metaplasia and total score after treatment（P〈0.05）.3Comparison of treatment before and after,there were statistically significant differences on the stomach pain,abdominal fullness,noisy,fatigue,anorexia andtotal score in both groups（P〈0.05）.Comparison between the two groups,there were statistically significant differences on the stomach pain,abdominal fullness,anorexia andtotal score after treatment（P〈0.05）.4Comparison of treatment before and after,there was statistically significant difference on the COX-2 in the treatment group（P〈0.05）.Comparison between the two groups,there was statistically significant difference on the COX-2 after treatment（P〈0.05）.Conclusion W

关 键 词：胃康宁 辛开苦降法 慢性萎缩性胃炎 胃癌前病变 临床疗效 机制研究 

分 类 号：R259[医药卫生—中西医结合]